Hemoglobin News and Research

RSS

CVD risk factors may differ between men and women with type 2 diabetes, shows study

Type 2 diabetes greatly increases a person's risk of developing cardiovascular disease (CVD). A new study showing that cardiovascular risk factors such as elevated blood pressure and cholesterol levels differ significantly between men and women is published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

16 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Protein Data Bank now contains over 100,000 structures

Spanning the globe from the US, UK, and Japan, the Worldwide Protein Data Bank (wwPDB) organization announces that the Protein Data Bank archive now contains more than 100,000 entries.

14 May 2014

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the first quarter ended March 31, 2014.

12 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Study: Mutations could have major impact on treatment of human blood diseases

A study published today in Nature Genetics has revealed mutations that could have a major impact on the future diagnosis and treatment of many human diseases.

29 Apr 2014

Oral health: The gateway to your overall health

If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.

25 Apr 2014

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

25 Apr 2014

Biomedical engineer develops highly innovative technology to make blood transfusions safer

A biomedical engineer at the University of Houston (UH) is working to develop highly innovative technology to make blood transfusions safer. His work is supported by a $1.8 million grant from the National Institutes of Health (NIH).

25 Apr 2014

Community-based structured weight loss program improves diabetes symptoms

Weight loss and control of blood sugar can reduce the risk of complications in patients with diabetes but this is difficult for many to achieve. A University of California, San Diego School of Medicine randomized controlled trial of obese adults with type 2 diabetes suggests that participants enrolled in a community-based structured weight loss program are able to shed more pounds, improve blood sugar control and reduce or eliminate insulin use and other medications compared to a control group.

25 Apr 2014

Zenalux, RPCI collaborate to enhance Zenascope system to detect oral cancers at an early stage

Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, is working with Roswell Park Cancer Institute to further enhance its flagship Zenascope™ product by adding a high-resolution camera to the system.

25 Apr 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013.

23 Apr 2014

New data-based model accurately estimates hemoglobin A1c using SMBG readings

Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes.

23 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Fewer blood transfusions reduce infection rates by nearly 20%

Blood transfusions are among the most common treatments for hospitalized patients nationwide, but doing them less often reduces infection rates by nearly 20 percent, according to a study in the Journal of the American Medical Association co-authored by Neil Blumberg, M.D., professor at the University of Rochester School of Medicine and Dentistry.

2 Apr 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

31 Mar 2014

NeuroVive Pharmaceutical initiates research collaboration with A1M Pharma

NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a collaboration agreement signed on 21 March 2014.

25 Mar 2014

Hemoglobin News and Research

CVD risk factors may differ between men and women with type 2 diabetes, shows study

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Protein Data Bank now contains over 100,000 structures

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Study: Mutations could have major impact on treatment of human blood diseases

Oral health: The gateway to your overall health

Researchers develop data-based model that accurately estimates A1c using self-monitored blood glucose

Biomedical engineer develops highly innovative technology to make blood transfusions safer

Community-based structured weight loss program improves diabetes symptoms

Zenalux, RPCI collaborate to enhance Zenascope system to detect oral cancers at an early stage

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

New data-based model accurately estimates hemoglobin A1c using SMBG readings

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Fewer blood transfusions reduce infection rates by nearly 20%

Bariatric surgery patients report better quality of life

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

NeuroVive Pharmaceutical initiates research collaboration with A1M Pharma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News